MedImmune Inc, San Diego, Calif, announced results from two important studies presented at the 2007 Infectious Diseases Society of America (IDSA) 45th Annual Meeting (October 4-7) adding to the body of knowledge about respiratory syncytial virus (RSV).
RSV is a viral pathogen that produces annual outbreaks usually between fall and spring. While RSV typically manifests cold-like symptoms in healthy children, it can prove to be a very serious respiratory illness for premature infants and is the leading cause of respiratory infections for newborns each year.
MedImmune presented new Phase 2 data at IDSA regarding motavizumab, a vaccine that the company is preparing for submission in the United States. Additional MedImmune initiatives presented at IDSA include:
• Safety, Tolerability, and Immunogenicity of Motavizumab in Young Children After a Second Season of RSV Prophylaxis (Fri, October 5)
• RSV Surveillance: Retrospective and Current Data on the Variance in Season Onsets and Offsets (Sat, October 6).
For additional information regarding the IDSA 45TH Annual Meeting, [removed]click here[/removed].
